India, July 13 -- Oncolytics Biotech Inc. (ONCY), a clinical-stage company, provided a clinical and regulatory update on REO 033, the company's study evaluating Pelareorep in combination for the second-line treatment of patients with Rat Sarcoma (RAS)-mutant, microsatellite stable (MSS) metastatic colorectal cancer.
Pelareorep is Oncolytics' lead investigational, intravenously delivered double-stranded RNA immunotherapeutic agent. The company is advancing Pelareorep in combination with chemotherapy and/or checkpoint inhibitors for the treatment of metastatic gastrointestinal cancers. Pelareorep has received Fast Track designation from the FDA for colorectal and pancreatic cancer.
REO 033 is a randomised controlled study evaluating Pelareo...